Phase 4
Completed N=114
The Effects of Arixtra on Wound Drainage Following Total Joint Arthroplasty
Total Knee Replacement
Source: ClinicalTrials.gov NCT00909064 ↗
Enrolled (actual)
114
Serious AEs
0.0%
Results posted
May 2017
Primary outcomePrimary: Number of Days Until a Dry Wound — 3.6 days
Summary
The investigators hypothesize that Arixtra patients will be less likely to experience wound infection than patients who have received low-molecular weight heparin, coumadin or aspirin with mechanical compression.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Days Until a Dry Wound |
3.6 | — |
| SECONDARY Number of Days in Hospital. |
3.73 | — |
| SECONDARY Incidence of Wound Infection |
2 | — |
Eligibility Criteria
Inclusion Criteria
- All primary unilateral TKA and THA cases will be included.
Exclusion Criteria
- Patients less than 50 kg, Patients with CrCl<30ml/min. Revision and bilateral procedures will be excluded.
Data sourced from ClinicalTrials.gov (NCT00909064). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.